A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Poziotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2017 Planned number of patients changed from 60 to 80.
- 18 Oct 2017 Results (n=8) presented at the 18th World Conference on Lung Cancer.
- 17 Oct 2017 According to a Spectrum Pharmaceuticals media release, interim results were presented at 18th IASLC World Conference on Lung Cancer in Japan.